Literature DB >> 21410061

High serum resistin in chronic viral hepatitis is not a marker of metabolic disorder.

C Morace1, A Spadaro, M Cucunato, V Tortorella, P Consolo, C Luigiano, G Stabile, C Bonfiglio, R Bellerone, A Fortiguerra, A Alibrandi, S Crinò, A Carducci, M L Resta, O Ferraù, M A Freni.   

Abstract

BACKGROUND/AIMS: The role of resistin, an adipocyte-secreted hormone, in insulin resistance and in inflammation is controversial. In chronic hepatitis C, insulin resistance, type 2 diabetes and liver steatosis are frequent and inconsistently correlated to circulating resistin levels. In this study we assessed if viral aetiology and host metabolic parameters influence serum resistin in patients with HCV- and HBV- related chronic hepatitis.
METHODOLOGY: Serum resistin was measured by ELISA and correlated to viral aetiology, age, gender, BMI, HOMA-IR, liver steatosis, hepatitis staging and grading, blood glucose, triglycerides and cholesterol in 43 patients with chronic hepatitis C, in 16 with chronic hepatitis B and in 29 healthy controls.
RESULTS: In both groups of patients resistin was significantly higher than in controls, with higher values in HBV- than in HCV-patients (p = 0.0007). Resistin levels were correlated to aetiology and, inversely, to age (p = 0.026), diabetes (p = 0.036) and steatosis (p = 0.029). Multiple regression analysis showed that resistin concentration was dependent only on the aetiology of liver disease (p = 0.001).
CONCLUSIONS: In chronic viral hepatitis serum resistin levels are high and not associated with altered metabolic parameters or with the histological activity of the disease. The meaning of higher resistin in HBV- than in HCV- chronic hepatitis is unclear.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21410061

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  1 in total

1.  P7170, a novel inhibitor of mTORC1/mTORC2 and Activin receptor-like Kinase 1 (ALK1) inhibits the growth of non small cell lung cancer.

Authors:  Venkatasubbaiah A Venkatesha; Asavari Joshi; Magesh Venkataraman; Vinay Sonawane; Dimple Bhatia; Prashant Tannu; Julie Bose; Sarika Choudhari; Ankita Srivastava; Prashant Kumar Pandey; Vaibhavi J Lad; Ramachandra Sangana; Tausif Ahmed; Anagha Damre; Vijaykumar Deore; Bichismita Sahu; Sanjay Kumar; Somesh Sharma; Veena R Agarwal
Journal:  Mol Cancer       Date:  2014-12-02       Impact factor: 27.401

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.